Last 12 months
Inside the activity.
0 purchase rows · 39 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 21 |
| Apr 2026 | 0 | 7 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2018 Filed Jul 24, 2018 20:32 UTC |
Bowden ChristopherChief Medical Officer
|
GrantPerformance share units · Derivative | 6,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-043729 · doc4.xml · derivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,265 Underlying: Common Stock · 6,265 shares Expires not disclosed F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:14 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-18-042453 · doc4.xml · derivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 Underlying: Common stock · 2,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:14 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 800 | $87.26 | $69,808.00 |
DisclosureSEC source: 0001209191-18-042453 · doc4.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $87.07 to $87.38. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:14 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 1,200 | $86.42 | $103,704.00 |
DisclosureSEC source: 0001209191-18-042453 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,724 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $86.07 to $87.06. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:14 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 2,000 | $35.16 | $70,320.00 |
DisclosureSEC source: 0001209191-18-042453 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 43 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 16:23 UTC |
Alenson CarmanPrincipal Accounting Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 272 | $0.00 Strike: $52.29 | $0.00 |
DisclosureSEC source: 0001209191-18-042326 · doc4.xml · derivative · entry 3 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,578 Underlying: Common stock · 272 shares Expires 2026-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on November 7, 2016. The shares underlying this option vest as to 25% of the underlying shares on November 7, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 16:23 UTC |
Alenson CarmanPrincipal Accounting Officer
|
SaleCommon stock | 272 | $84.94 | $23,103.68 |
DisclosureSEC source: 0001209191-18-042326 · doc4.xml · nonDerivative · entry 2 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 16:23 UTC |
Alenson CarmanPrincipal Accounting Officer
|
Exercise / conversionCommon stock | 272 | $52.29 | $14,222.88 |
DisclosureSEC source: 0001209191-18-042326 · doc4.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:08 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock options (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-041982 · doc4.xml · derivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:08 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 300 | $84.32 | $25,296.00 |
DisclosureSEC source: 0001209191-18-041982 · doc4.xml · nonDerivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $84.07 to $84.69. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:08 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 2,700 | $83.41 | $225,207.00 |
DisclosureSEC source: 0001209191-18-041982 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,496 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $83.01 to $83.68. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:08 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionCommon stock | 3,000 | $9.05 | $27,150.00 |
DisclosureSEC source: 0001209191-18-041982 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 05, 2018 Filed Aug 10, 2018 21:20 UTC Amendment |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-046269 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 20:02 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,050 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-039501 · doc4.xml · derivative · entry 3 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,750 Underlying: Common stock · 2,050 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 20:02 UTC |
Hoerter Steven L.Chief Commercial Officer
|
SaleCommon stock | 2,050 | $97.58 | $200,039.00 |
DisclosureSEC source: 0001209191-18-039501 · doc4.xml · nonDerivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 20:02 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionCommon stock | 2,050 | $39.76 | $81,508.00 |
DisclosureSEC source: 0001209191-18-039501 · doc4.xml · nonDerivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:05 UTC |
Foster-Cheek Kaye IDirector
|
Exercise / conversionStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $50.73 | $0.00 |
DisclosureSEC source: 0001209191-18-038277 · doc4.xml · derivative · entry 5 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 9,000 shares Expires 2027-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:05 UTC |
Foster-Cheek Kaye IDirector
|
SaleCommon stock | 839 | $94.30 | $79,117.70 |
DisclosureSEC source: 0001209191-18-038277 · doc4.xml · nonDerivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $94.21 to $94.63. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:05 UTC |
Foster-Cheek Kaye IDirector
|
SaleCommon stock | 5,980 | $93.78 | $560,804.40 |
DisclosureSEC source: 0001209191-18-038277 · doc4.xml · nonDerivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,039 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $93.15 to $94.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:05 UTC |
Foster-Cheek Kaye IDirector
|
SaleCommon stock | 2,181 | $92.62 | $202,004.22 |
DisclosureSEC source: 0001209191-18-038277 · doc4.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,019 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $92.14 to $93.11. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:05 UTC |
Foster-Cheek Kaye IDirector
|
Exercise / conversionCommon stock | 9,000 | $50.73 | $456,570.00 |
DisclosureSEC source: 0001209191-18-038277 · doc4.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:23 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-18-037724 · doc4.xml · derivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common stock · 2,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:23 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 200 | $93.37 | $18,674.00 |
DisclosureSEC source: 0001209191-18-037724 · doc4.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $93.31 to $93.52. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:23 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 1,800 | $92.84 | $167,112.00 |
DisclosureSEC source: 0001209191-18-037724 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,081 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $92.28 to $93.08. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:23 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 2,000 | $35.16 | $70,320.00 |
DisclosureSEC source: 0001209191-18-037724 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:02 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock options (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-036320 · doc4.xml · derivative · entry 5 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:02 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 939 | $94.28 | $88,528.92 |
DisclosureSEC source: 0001209191-18-036320 · doc4.xml · nonDerivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $94.13 to $94.45. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:02 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 1,259 | $93.27 | $117,426.93 |
DisclosureSEC source: 0001209191-18-036320 · doc4.xml · nonDerivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,135 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $92.96 to $93.79. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:02 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 802 | $92.45 | $74,144.90 |
DisclosureSEC source: 0001209191-18-036320 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,394 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $91.90 to $92.87. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:02 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionCommon stock | 3,000 | $9.05 | $27,150.00 |
DisclosureSEC source: 0001209191-18-036320 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 05, 2018 Filed Aug 10, 2018 21:19 UTC Amendment |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-046268 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:10 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 108 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001209191-18-035615 · doc4.xml · derivative · entry 10 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,619 Underlying: Common stock · 108 shares Expires 2022-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: This option was granted on April 6, 2012 for the purchase of 72,727 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013, resulting in the vesting of the option as to 18,181 shares. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 36,364 shares, and the remaining 18,182 shares vested on April 4, 2015. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:10 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 12,892 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-18-035615 · doc4.xml · derivative · entry 9 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 12,892 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: This option was granted on March 2, 2011. The shares underlying this option vested as to 25% of the shares on the date of grant and as to 25% of the shares upon the achievement of a performance milestone on July 19, 2013. The remaining 50% of the shares underlying the option vested in equal monthly installments through July 19, 2015. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:10 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 100 | $96.91 | $9,691.00 |
DisclosureSEC source: 0001209191-18-035615 · doc4.xml · nonDerivative · entry 6 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:10 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 3,190 | $96.40 | $307,516.00 |
DisclosureSEC source: 0001209191-18-035615 · doc4.xml · nonDerivative · entry 5 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $95.83 to $96.80. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:10 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 8,200 | $95.11 | $779,902.00 |
DisclosureSEC source: 0001209191-18-035615 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,290 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $94.73 to $95.70. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:10 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 1,510 | $94.37 | $142,498.70 |
DisclosureSEC source: 0001209191-18-035615 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,490 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $93.72 to $94.71. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:10 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 108 | $2.34 | $252.72 |
DisclosureSEC source: 0001209191-18-035615 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:10 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 12,892 | $0.47 | $6,027.01 |
DisclosureSEC source: 0001209191-18-035615 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:26 UTC |
MARAGANORE JOHNDirector
|
GrantRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035082 · doc4.xml · derivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:26 UTC |
MARAGANORE JOHNDirector
|
GrantStock option (right to buy) · Derivative | 5,700 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001209191-18-035082 · doc4.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:28 UTC |
Scadden DavidDirector
|
GrantRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035091 · doc4.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:28 UTC |
Scadden DavidDirector
|
GrantStock option (right to buy) · Derivative | 5,700 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001209191-18-035091 · doc4.xml · derivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:23 UTC |
Ho MaykinDirector
|
GrantRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035070 · doc4.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:23 UTC |
Ho MaykinDirector
|
GrantStock option (right to buy) · Derivative | 5,700 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001209191-18-035070 · doc4.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:19 UTC |
FOUSE JACQUALYN ADirector
|
GrantRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035052 · doc4.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:19 UTC |
FOUSE JACQUALYN ADirector
|
GrantStock option (right to buy) · Derivative | 5,700 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001209191-18-035052 · doc4.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:17 UTC |
Foster-Cheek Kaye IDirector
|
GrantRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035041 · doc4.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:17 UTC |
Foster-Cheek Kaye IDirector
|
GrantStock option (right to buy) · Derivative | 5,700 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001209191-18-035041 · doc4.xml · derivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:10 UTC |
Clancy Paul JDirector
|
GrantRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035022 · doc4.xml · derivative · entry 2 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.